Artiva cryopreserved universal NK cells exhibit superior tumor resistance without the need for gene editing

November 14, 2022 /eMedClub News/-- Recently, Artiva, a star NK cell therapy company, presented preclinical data
on its cord blood-derived and cryopreserved NK cell therapy candidate AB-101 in combination with monoclonal antibody for the treatment of a variety of tumors at the SITC 2022 Annual Conference.

AB-101 is a cord blood-derived, allogeneic, cryopreservation, ADCC (antibody-dependent cell-mediated cytotoxicity) enhanced NK cell therapy candidate that can be used
in combination with monoclonal antibodies or innate cell junctions.
The product uses cord blood with high CD16 receptor affinity and KIR-B haplotype as the source, which has high cell viability
.

In addition, based on the proprietary technology platform, the AlloNK platform, Artiva can generate thousands of doses of pure, cryopreservation, transfusion-ready NK cells from a single cord blood while maintaining high and consistent CD16 expression without the need for gene editing
.
Artiva procures and screens NK cells derived from primary cord blood, and then expands and activates
NK cells using proprietary eFeeders, cells, and industrial bioreactors.
Cryopreservation steps are established throughout the process, including the final finished product, which can achieve a long shelf life
at low temperatures.

Artiva is conducting a Phase 1/2 multicenter clinical trial (NCT04673617) to evaluate the clinical efficacy
of AB-101 alone and in combination with rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
Artiva is also developing a combination therapy consisting of AB-101 and AFM13, Affimed's flagship product, the NK Cell Junction, for the treatment of patients
with relapsed/refractory CD30-positive lymphoma.

It is worth mentioning that Affimed recently announced the latest clinical data of its universal NK cell therapy in combination with NK cell adaptor AFM13 for the treatment of refractory CD30+ lymphoma, and the results showed that among 24 CD30-positive lymphoma patients who received the phase 2 clinical recommended dose (highest dose group), the combination therapy achieved an overall response rate of 100% (24/24) and a complete response rate
of 70.
8% (17/24).

The preclinical data provided by Artiva underscores the superiority of its AlloNK platform, which generates NK cell products with high activity with consistent CD16 receptors and other receptors involved in antitumor activity, including NKG2D, DNAM-1, NKp30, and NKp46, so these NK cell products do not need to be modified and can be cryopreservation
.
AB-101 generated by this platform technology is combined with monoclonal antibody to produce antitumor activity
in various solid tumors and hematopoietic model systems.

"These data provide additional support for AB-101 as a candidate for a highly scaled, off-the-shelf, ADCC-enhanced NK cell product that outperforms common NK cells and requires no genetic modification
.
" Dr.
Peter Flynn, co-founder and COO of Artiva, said, "Specifically, these data support AB-101's enhanced ADCC activity when combined with antibodies such as Rituxan ®, Gazyva ®, Erbitux ®, and Herceptin ®, highlighting the broad therapeutic potential
of AB-101.
”

Resources:

1.
style="margin: 0px 16px;padding: 0px;clear: both;min-height: 1em;color: rgb(51, 51, 51);font-family: mp-quote, -apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-align: justify;text-indent: 0px;text-transform: none;white-space: normal;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;max-width: 100%;line-height: normal;overflow-wrap: break-word !important;box-sizing: border-box !important;">

——List of recent popular events——